Fairmount Funds Management LLC’s activist stake in Apogee Therapeutics fell from greater than 5% to 0.0%, or 0.00 shares, after the merger. Shares were converted into the right to receive $135.11 per share in cash, while the voting agreement ended and the directors resigned at the merger’s effective time.
Key Highlights
- Apogee Therapeutics’ directors, including Tomas Kiselak, resigned immediately before the Merger took effect.
- The voting agreement automatically ended when the merger was completed and has no further force or effect.
- Fairmount Funds Management LLC’s reported activist stake fell from greater than 5% to 0.0% after the merger.
Apogee Therapeutics, Inc. (NASDAQ: APGE) saw Fairmount Funds Management LLC’s activist position fall from greater than 5% to 0.0% on September 3, 2026. The reporting persons now hold 0.00 shares and no longer beneficially own securities of Apogee Therapeutics. The merger was completed on that date, with the company surviving as a Wholly Owned Subsidiary of Parent.
Fairmount Position Reaches Zero
Fairmount Funds Management LLC was listed alongside Fairmount Healthcare Fund II L.P. Peter Evan Harwin and Tomas Kiselak in the activist ownership group. Each reported 0.0% ownership after the transaction, with the listed share positions shown as 0.00. The ownership change followed the completion of the merger contemplated by an agreement dated June 18, 2026.
Cash Replaces Common Stock
Peter Evan Harwin exercised 42,208 vested director’s stock Options for 42,208 common shares on August 7, 2026.
Voting Agreement Ends
The voting agreement automatically terminated when the merger was consummated. It has no further force or effect. Apogee Therapeutics’ directors, including Tomas Kiselak, resigned immediately before the merger became effective and ceased serving on the board. The company continued as a wholly owned subsidiary of Parent following completion of the transaction.
FAQs
Q: What happened to Fairmount Funds Management’s Apogee Therapeutics stake?
A: Fairmount Funds Management LLC’s reported activist stake fell from greater than 5% to 0.0% after the merger. The reporting persons no longer beneficially own any Apogee Therapeutics securities.
Q: Did Apogee Therapeutics’ voting agreement remain active?
A: The voting agreement automatically terminated upon consummation of the merger. The filing states that it has no further force or effect.
Q: What happened to the reporting persons’ Apogee shares and stock options?
A: Their stock options were canceled and converted into rights to receive the excess of that amount over the applicable exercise price.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.